[Excenen PharmaTech 한국공식대리점] Blu-945 (EGFR inhibitor)

어스바이오는 Excenen PharmaTech 한국 공식 대리점으로서 모든 제품을 전문적으로 취급 및 공급하고 있습니다.
Excenen PharmaTech의 EGFR inhibitor 제품을 소개드립니다.

 

BLU-945은 강력하고 선택성이 높으며 가역적이고 경구 투여 가능한 epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs)입니다. BLU-945은 L858R 및/또는 exon 19 deletion mutation, T790M mutation 및 C797S mutation를 가진 EGFR을 효과적으로 억제할 수 있습니다.
 

Synonyms:	BLU945
CAS No.:	2660250-10-0
Purity:	>99.5% (new batch)
Formula:	C28H37FN6O3S
Mol Weight:	556.695
Appearance:	solid powder
Solubility:	Soluble in DMSO
Shelf Life:	>2 years if stored properly
Storage:	Powder -20℃ 2 years; In solvent -20℃ 1 month
Shipping:	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:

[1]. Meredith S Eno, et al. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. J Med Chem. 2022 Jul 28;65(14):9662-9677.

[2]. Sun Min Lim, et al. BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitor with intracranial activity, demonstrates robust in vivo anti-tumor activity in models of osimertinib-resistant non-small cell lung cancer.

[3]. John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1.

[4]. Elaine Shum. et al. A phase 1/2 study of BLU-945 in patients with common activating EGFRmutant non-small cell lung cancer (NSCLC) (SYMPHONY trial-in-progress)

---